TY - JOUR T1 - The impact of host resistance on cumulative mortality and the threshold of herd immunity for SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.07.15.20154294 SP - 2020.07.15.20154294 AU - José Lourenço AU - Francesco Pinotti AU - Craig Thompson AU - Sunetra Gupta Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/01/2020.07.15.20154294.abstract N2 - The risk of severe disease and death from COVID-19 is not uniformly distributed across all age classes, with the bulk of deaths occurring among older ages and those with comorbidities. Evidence is also mounting that some individuals have pre-existing immune responses to SARS-CoV-2 which may confer resistance to infection. We present a general mathematical framework which can be used to systematically explore the impact of variation in resistance to severe disease and infection by SARS-CoV-2 on its epidemiology. We find that the herd immunity threshold (HIT) can be lowered by the existence of a fraction of the population who are unable to transmit the virus, whether they are effectively segregated from the general population or mix randomly. These results help to explain the wide variation observed globally in seroprevalence and cumulative deaths and raise the possibility that the proportion exposed may have already exceeded HIT in certain regions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNothing to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No details are required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data is included. ER -